From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2020-06, Vol.21 (11), p.4067
Hauptverfasser: Montemagno, Christopher, Cassim, Shamir, Pouyssegur, Jacques, Broisat, Alexis, Pagès, Gilles
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page 4067
container_title International journal of molecular sciences
container_volume 21
creator Montemagno, Christopher
Cassim, Shamir
Pouyssegur, Jacques
Broisat, Alexis
Pagès, Gilles
description Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.
doi_str_mv 10.3390/ijms21114067
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7312874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2411918032</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-e0e57ac128a72a08a88773b0e5c8c052d6fcb482bf1b9d22cce1865d2051cb73</originalsourceid><addsrcrecordid>eNpdkU1PGzEQhq2KqlDojTOyxKWHpvXHbuxwQIrS0iKB4JC7Neud3TjatYPtpeq_rykUpZVGmpH9zDszegk55eyzlAv2xW3HJDjnFZurN-SIV0LMWKkP9upD8j6lLWNCinrxjhyWxBXX_Ij8vIphpLcwuN6Dz_Q-hj5iSi54mgNdbzDCDqfsLF1D7DE731_Q1RQjFvraJ9dvcqKho7eYQt7g4DwtcQ_eRoSnvq-TzTDQZYs-WIjW-TDCCXnbwZDww0s-Juurb-vVj9nN3ffr1fJmZiul8wwZ1gosFxqUAKZBa6VkU16ttqwW7byzTaVF0_Fm0QphLXI9r1vBam4bJY_J5bPsbmpGbG1ZOsJgdtGNEH-ZAM78--PdxvTh0ShZZqqqCHx8EYjhYcKUzeiSxWEAj2FKRlSc17VUTBb0_D90G6boy3V_qAXXTIpCfXqmbAwpRexel-HMPBlq9g0t-Nn-Aa_wXwflb7ijnnk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2411918032</pqid></control><display><type>article</type><title>From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma</title><source>MEDLINE</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Montemagno, Christopher ; Cassim, Shamir ; Pouyssegur, Jacques ; Broisat, Alexis ; Pagès, Gilles</creator><creatorcontrib>Montemagno, Christopher ; Cassim, Shamir ; Pouyssegur, Jacques ; Broisat, Alexis ; Pagès, Gilles</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21114067</identifier><identifier>PMID: 32517181</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Angiogenesis ; Antigens, Neoplasm - genetics ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - metabolism ; Apoptosis ; Biomarkers, Tumor ; Breast cancer ; Cancer therapies ; Cancer Vaccines - therapeutic use ; Carcinoma, Pancreatic Ductal - diagnosis ; Carcinoma, Pancreatic Ductal - etiology ; Carcinoma, Pancreatic Ductal - therapy ; Cell adhesion &amp; migration ; Cell growth ; Cell Proliferation ; Chemotherapy ; Clinical trials ; Combined Modality Therapy ; Cyclin-dependent kinases ; Disease Management ; Disease Progression ; Disease Susceptibility ; Drug Development ; GPI-Linked Proteins - genetics ; GPI-Linked Proteins - immunology ; GPI-Linked Proteins - metabolism ; Humans ; Kinases ; Medical prognosis ; Mesothelin ; Mesothelioma ; Metastasis ; Molecular Targeted Therapy ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Ovarian cancer ; Pancreas ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - immunology ; Pancreatic Neoplasms - therapy ; Pericardium ; Peritoneum ; Pleura ; Prognosis ; Proteins ; Review ; Therapeutic targets ; Tumors</subject><ispartof>International journal of molecular sciences, 2020-06, Vol.21 (11), p.4067</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-e0e57ac128a72a08a88773b0e5c8c052d6fcb482bf1b9d22cce1865d2051cb73</citedby><cites>FETCH-LOGICAL-c478t-e0e57ac128a72a08a88773b0e5c8c052d6fcb482bf1b9d22cce1865d2051cb73</cites><orcidid>0000-0002-8466-5610 ; 0000-0002-4265-8463 ; 0000-0003-2779-6902 ; 0000-0002-5687-1812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312874/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312874/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32517181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montemagno, Christopher</creatorcontrib><creatorcontrib>Cassim, Shamir</creatorcontrib><creatorcontrib>Pouyssegur, Jacques</creatorcontrib><creatorcontrib>Broisat, Alexis</creatorcontrib><creatorcontrib>Pagès, Gilles</creatorcontrib><title>From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.</description><subject>Adenocarcinoma</subject><subject>Angiogenesis</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Apoptosis</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Carcinoma, Pancreatic Ductal - diagnosis</subject><subject>Carcinoma, Pancreatic Ductal - etiology</subject><subject>Carcinoma, Pancreatic Ductal - therapy</subject><subject>Cell adhesion &amp; migration</subject><subject>Cell growth</subject><subject>Cell Proliferation</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Cyclin-dependent kinases</subject><subject>Disease Management</subject><subject>Disease Progression</subject><subject>Disease Susceptibility</subject><subject>Drug Development</subject><subject>GPI-Linked Proteins - genetics</subject><subject>GPI-Linked Proteins - immunology</subject><subject>GPI-Linked Proteins - metabolism</subject><subject>Humans</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Mesothelin</subject><subject>Mesothelioma</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Metastasis</subject><subject>Ovarian cancer</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - immunology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Pericardium</subject><subject>Peritoneum</subject><subject>Pleura</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Review</subject><subject>Therapeutic targets</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1PGzEQhq2KqlDojTOyxKWHpvXHbuxwQIrS0iKB4JC7Neud3TjatYPtpeq_rykUpZVGmpH9zDszegk55eyzlAv2xW3HJDjnFZurN-SIV0LMWKkP9upD8j6lLWNCinrxjhyWxBXX_Ij8vIphpLcwuN6Dz_Q-hj5iSi54mgNdbzDCDqfsLF1D7DE731_Q1RQjFvraJ9dvcqKho7eYQt7g4DwtcQ_eRoSnvq-TzTDQZYs-WIjW-TDCCXnbwZDww0s-Juurb-vVj9nN3ffr1fJmZiul8wwZ1gosFxqUAKZBa6VkU16ttqwW7byzTaVF0_Fm0QphLXI9r1vBam4bJY_J5bPsbmpGbG1ZOsJgdtGNEH-ZAM78--PdxvTh0ShZZqqqCHx8EYjhYcKUzeiSxWEAj2FKRlSc17VUTBb0_D90G6boy3V_qAXXTIpCfXqmbAwpRexel-HMPBlq9g0t-Nn-Aa_wXwflb7ijnnk</recordid><startdate>20200606</startdate><enddate>20200606</enddate><creator>Montemagno, Christopher</creator><creator>Cassim, Shamir</creator><creator>Pouyssegur, Jacques</creator><creator>Broisat, Alexis</creator><creator>Pagès, Gilles</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8466-5610</orcidid><orcidid>https://orcid.org/0000-0002-4265-8463</orcidid><orcidid>https://orcid.org/0000-0003-2779-6902</orcidid><orcidid>https://orcid.org/0000-0002-5687-1812</orcidid></search><sort><creationdate>20200606</creationdate><title>From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma</title><author>Montemagno, Christopher ; Cassim, Shamir ; Pouyssegur, Jacques ; Broisat, Alexis ; Pagès, Gilles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-e0e57ac128a72a08a88773b0e5c8c052d6fcb482bf1b9d22cce1865d2051cb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenocarcinoma</topic><topic>Angiogenesis</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Apoptosis</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Carcinoma, Pancreatic Ductal - diagnosis</topic><topic>Carcinoma, Pancreatic Ductal - etiology</topic><topic>Carcinoma, Pancreatic Ductal - therapy</topic><topic>Cell adhesion &amp; migration</topic><topic>Cell growth</topic><topic>Cell Proliferation</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Cyclin-dependent kinases</topic><topic>Disease Management</topic><topic>Disease Progression</topic><topic>Disease Susceptibility</topic><topic>Drug Development</topic><topic>GPI-Linked Proteins - genetics</topic><topic>GPI-Linked Proteins - immunology</topic><topic>GPI-Linked Proteins - metabolism</topic><topic>Humans</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Mesothelin</topic><topic>Mesothelioma</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Metastasis</topic><topic>Ovarian cancer</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - immunology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Pericardium</topic><topic>Peritoneum</topic><topic>Pleura</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Review</topic><topic>Therapeutic targets</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montemagno, Christopher</creatorcontrib><creatorcontrib>Cassim, Shamir</creatorcontrib><creatorcontrib>Pouyssegur, Jacques</creatorcontrib><creatorcontrib>Broisat, Alexis</creatorcontrib><creatorcontrib>Pagès, Gilles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montemagno, Christopher</au><au>Cassim, Shamir</au><au>Pouyssegur, Jacques</au><au>Broisat, Alexis</au><au>Pagès, Gilles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-06-06</date><risdate>2020</risdate><volume>21</volume><issue>11</issue><spage>4067</spage><pages>4067-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32517181</pmid><doi>10.3390/ijms21114067</doi><orcidid>https://orcid.org/0000-0002-8466-5610</orcidid><orcidid>https://orcid.org/0000-0002-4265-8463</orcidid><orcidid>https://orcid.org/0000-0003-2779-6902</orcidid><orcidid>https://orcid.org/0000-0002-5687-1812</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2020-06, Vol.21 (11), p.4067
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7312874
source MEDLINE; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Adenocarcinoma
Angiogenesis
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Antigens, Neoplasm - metabolism
Apoptosis
Biomarkers, Tumor
Breast cancer
Cancer therapies
Cancer Vaccines - therapeutic use
Carcinoma, Pancreatic Ductal - diagnosis
Carcinoma, Pancreatic Ductal - etiology
Carcinoma, Pancreatic Ductal - therapy
Cell adhesion & migration
Cell growth
Cell Proliferation
Chemotherapy
Clinical trials
Combined Modality Therapy
Cyclin-dependent kinases
Disease Management
Disease Progression
Disease Susceptibility
Drug Development
GPI-Linked Proteins - genetics
GPI-Linked Proteins - immunology
GPI-Linked Proteins - metabolism
Humans
Kinases
Medical prognosis
Mesothelin
Mesothelioma
Metastasis
Molecular Targeted Therapy
Neoplasm Invasiveness
Neoplasm Metastasis
Ovarian cancer
Pancreas
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Pericardium
Peritoneum
Pleura
Prognosis
Proteins
Review
Therapeutic targets
Tumors
title From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20Malignant%20Progression%20to%20Therapeutic%20Targeting:%20Current%20Insights%20of%20Mesothelin%20in%20Pancreatic%20Ductal%20Adenocarcinoma&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Montemagno,%20Christopher&rft.date=2020-06-06&rft.volume=21&rft.issue=11&rft.spage=4067&rft.pages=4067-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21114067&rft_dat=%3Cproquest_pubme%3E2411918032%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2411918032&rft_id=info:pmid/32517181&rfr_iscdi=true